Vertex PharmaceuticalsBSP:VRTX34 87 EV-to-FCF is 29.57 as of Jul. 01, 2026, which is 4% above its 10-year median of 28.30. GuruFocus rates BSP:VRTX34 with a GF Score™ of 87/100 and a GF Value™ of R$614.03 (Fairly Valued). The stock has 4 warning signs investors should review. Among 331 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 67.07% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vertex Pharmaceuticals's Enterprise Value is R$589,210 Mil.
Vertex Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was R$19,927 Mil. Therefore, Vertex Pharmaceuticals's EV-to-FCF for today is 29.57.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-FCF or its related term are showing as below:
BSP:VRTX34'
s EV-to-FCF Range Over the Past 10 Years
Min: -442.71 Med: 28.3 Max: 338.44
Current: 32.56
During the past 13 years, the highest EV-to-FCF of Vertex Pharmaceuticals was 338.44. The lowest was -442.71. And the median was 28.30.
BSP:VRTX34's EV-to-FCF is ranked worse than 67.07% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs BSP:VRTX34: 32.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vertex Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Vertex Pharmaceuticals's share price for today is R$607.20.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$22.761.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:VRTX34 vs REGN, ALNY, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-FCF falls into.
Vertex Pharmaceuticals's current Enterprise Value is R$589,210 Mil.
Vertex Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$19,927 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (BSP:VRTX34) has a EV-to-FCF of 29.57 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vertex Pharmaceuticals and its competitors. This is near median its historical median of 28.30. According to the industry distribution chart, Vertex Pharmaceuticals ranks #222 out of 331 companies in the Biotechnology industry, placing it in the top 67.1%.
Is Vertex Pharmaceuticals' EV-to-FCF too high?
Vertex Pharmaceuticals' current EV-to-FCF of 29.57 is near median its 10-year median of 28.30. The Biotechnology industry median EV-to-FCF is 15.90. Vertex Pharmaceuticals' value of 29.57 is 86% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #222 out of 331 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' EV-to-FCF compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #222 out of 331 companies for EV-to-FCF. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 15.90. Vertex Pharmaceuticals' value of 29.57 is 86% above this benchmark. While the company's 10-year median is 28.30 vs. the industry median of 15.90, Vertex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current EV-to-FCF of 29.57 is 86% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current EV-to-FCF is 29.57, which is near median its own 10-year median of 28.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (BSP:VRTX34) is currently considered Fairly Valued. The stock's GF Value™ is R$614.03, compared to a current price of R$607.20 — trading 1.1% below its estimated fair value. The current EV-to-FCF is 29.57, which is near median its 10-year median of 28.30 and 86% above the Biotechnology industry median of 15.90. Vertex Pharmaceuticals' overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vertex Pharmaceuticals (BSP:VRTX34), the current EV-to-FCF is 29.57 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (BSP:VRTX34) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of R$607.20 is trading 1.1% below its estimated GF Value™ of R$614.03.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for BSP:VRTX34:
EV-to-FCF: 29.57 (near median its 10-year median of 28.30)
GF Value™: R$614.03 vs. price of R$607.20 (1.1% below fair value)
Industry Position: 86% above the Biotechnology median (#222 of 331)
No single metric tells the full story. See the BSP:VRTX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
87GF Score
Get the complete analysis for BSP:VRTX34
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:VRTX34 has been successfully added to your 
